Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections
Related Posts
Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
